Recent advances in developing targeted protein degraders

被引:0
|
作者
Cheng, Binbin [1 ,2 ]
Li, Hongqiao [3 ]
Peng, Xiaopeng [4 ]
Chen, Jianjun [5 ]
Shao, Chuxiao [2 ]
Kong, Zhihua [6 ]
机构
[1] Hubei Polytech Univ, Hubei Key Lab Kidney Dis Pathogenesis & Intervent, Huangshi 435003, Peoples R China
[2] Wenzhou Med Univ, Lishui Peoples Hosp, Cent Lab, Lishui Hosp, Lishui 323000, Zhejiang, Peoples R China
[3] Cent Hosp Huangshi, Huangshi 435000, Peoples R China
[4] Gannan Med Univ, Coll Pharm, Ganzhou 314000, Peoples R China
[5] Southern Med Univ, Sch Pharmaceut Sci, Guangdong Prov Key Lab New Drug Screening, NMPA Key Lab Res & Evaluat Drug Metab, Guangzhou 510515, Peoples R China
[6] Guangdong Prov Hosp, Integrated Tradit Chinese & Western Med, Foshan 528200, Peoples R China
基金
中国国家自然科学基金;
关键词
Targeted protein degradation; Small molecule ligands; PROTACs; Molecular glues; LYTACs; HyTTD; ANTIBODY-BASED PROTACS; MDM2; INHIBITORS; CANCER-THERAPY; DEGRADATION; DISCOVERY; LIGASE; ASGPR; POTENT;
D O I
10.1016/j.ejmech.2024.117212
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Targeted protein degradation (TPD) represents a promising therapeutic approach, encompassing several innovative strategies, including but not limited to proteolysis targeting chimeras (PROTACs), molecular glues, hydrophobic tag tethering degraders (HyTTD), and lysosome-targeted chimeras (LYTACs). Central to TPD are small molecule ligands, which play a critical role in mediating the degradation of target proteins. This review summarizes the current landscape of small molecule ligands for TPD molecules. These small molecule ligands can utilize the proteasome, lysosome, autophagy, or hydrophobic-tagging system to achieve the degradation of target proteins. The article mainly focuses on introducing their design principles, application advantages, and potential limitations. A brief discussion on the development prospects and future directions of TPD technology was also provided.
引用
收藏
页数:19
相关论文
共 50 条
  • [41] RECENT ADVANCES IN DEVELOPING THE CFOSAT SCATTEROMETER
    Zhu, Di
    Dong, Xiaolong
    Yun, Risheng
    Xu, Xingou
    2016 IEEE INTERNATIONAL GEOSCIENCE AND REMOTE SENSING SYMPOSIUM (IGARSS), 2016, : 5801 - 5803
  • [42] Targeted protein degraders: a call for collective action to advance safety assessment
    Jones, Lyn H.
    Mitchell, Constance A.
    Loberg, Lise
    Pavkovic, Mira
    Rao, Mohan
    Roberts, Ruth
    Stamp, Katie
    Volak, Laurie
    Wittwer, Matthias B.
    Pettit, Syril
    NATURE REVIEWS DRUG DISCOVERY, 2022, 21 (06) : 401 - 402
  • [43] Recent Advances in Systematic and Targeted Prostate Biopsies
    Devetzis, Konstantinos
    Kum, Francesca
    Popert, Richard
    RESEARCH AND REPORTS IN UROLOGY, 2021, 13 : 799 - 809
  • [44] Recent advances in targeted therapy for pancreatic adenocarcinoma
    Fang, Yu-Ting
    Yang, Wen-Wei
    Niu, Ya-Ru
    Sun, Yong-Kun
    WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY, 2023, 15 (04) : 571 - 595
  • [45] Recent advances in targeted proteomics for clinical applications
    Domon, Bruno
    Gallien, Sebastien
    PROTEOMICS CLINICAL APPLICATIONS, 2015, 9 (3-4) : 423 - 431
  • [46] Recent advances in bone-targeted therapy
    Shi, Chen
    Wu, Tingting
    He, Yu
    Zhang, Yu
    Fu, Dehao
    PHARMACOLOGY & THERAPEUTICS, 2020, 207
  • [47] Recent Advances in Targeted Nanotherapies for Ischemic Stroke
    Liao, Jun
    Li, Yi
    Luo, Yunchun
    Meng, Sha
    Zhang, Chuan
    Xiong, Liyan
    Wang, Tingfang
    Lu, Ying
    MOLECULAR PHARMACEUTICS, 2022, 19 (09) : 3026 - 3041
  • [48] Recent Advances in Targeted Therapies for Infantile Hemangiomas
    Liang, Tiantian
    Liu, Xianbin
    Tong, Yujun
    Ding, Qian
    Yang, Min
    Ning, Hong
    INTERNATIONAL JOURNAL OF NANOMEDICINE, 2024, 19 : 6127 - 6143
  • [49] Recent Advances of Hepsin-Targeted Inhibitors
    Kwon, Hongmok
    Han, JooYeon
    Lee, Ki-Yong
    Son, Sang-Hyun
    Byun, Youngjoo
    CURRENT MEDICINAL CHEMISTRY, 2017, 24 (21) : 2294 - 2311
  • [50] Recent advances in targeted therapy for ovarian cancer
    Tianyu Qin
    Gang Chen
    Oncology and Translational Medicine, 2022, 8 (01) : 28 - 35